CoChat
Sign Up
Cited by 54Mesenchymal stem cell researchLiver physiology and pathologyLiver Disease and Transplantation

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Overexpression of c-Met in bone marrow mesenchymal stem cells improves their effectiveness in homing and repair of acute liver failure

Open access
Wang, Kun, Li, Yuwen, Zhu, Tiantian, Zhang, Yongting, Li, Wenting, Lin, Wenyu, Li, Jun, Zhu, Chuanlong·2017·Stem Cell Research & Therapy
DOI 10.1186/s13287-017-0614-2PMC PMC5499016
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Transplantation of bone marrow-derived mesenchymal stem cells (BMSCs) has emerged as a novel therapy for acute liver failure (ALF). However, the homing efficiency of BMSCs to the injured liver sites appears to be poor. In this study, we aimed to determine if overexpression of c-Met in BMSCs could promote the homing ability of BMSCs to rat livers affected by ALF. METHODS: Overexpression of c-Met in BMSCs (c-Met-BMSCs) was attained by transfection of naive BMSCs with the lenti-c-Met-GFP. The impact of transplanted c-Met-BMSCs on both homing and repair of ALF was evaluated and compared with lenti-GFP empty vector transfected BMSCs (control BMSCs). RESULTS: After cells were transfected with the lenti-c-Met-GFP vector, the BMSCs displayed very high expression of c-Met protein as demonstrated by Western blot. In addition, in vitro transwell migration assays showed that the migration ability of c-Met-BMSCs was significantly increased in comparison with that of control BMSCs (P < 0.05), and was dependent on hepatocyte growth factor (HGF). Furthermore, rats with ALF that received transplanted c-Met-BMSCs showed significantly improved homing ability to the injured liver; this was accompanied by elevated survival rates and liver function in the ALF rats. Parallel pathological examination further confirmed that transplantation of c-Met-BMSCs ameliorated liver injury with reduced hepatic activity index (HAI) scores, and that the effects of c-Met-BMSCs were more profound than those of control BMSCs. CONCLUSIONS: Overexpression of c-Met promotes the homing of BMSCs to injured hepatic sites in a rat model of ALF, thereby improving the efficacy of BMSC therapy for ALF repair.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-017-0614-2

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MSC overexpression with c-met and CXCR4 improves homing to the livers of acute liver failure rodent models.

    “Regarding liver diseases, MSC overexpression with c-met and CXCR4 improved homing to the livers of acute liver failure rodent models [156], [157], resulting in enhanced liver function and increased survival rates.”

    From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [156]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 36

  1. Cai Y, Zou Z, Liu L, Chen S, Chen Y, Lin Z, Shi K, Xu L, Chen Y. Bone marrow-derived mesenchymal stem cells inhibits hepatocyte apoptosis after acute liver injury. Int J Clin Exp Pathol. 2015;8(1):107–16.
  2. Basto ST, Villela-Nogueira CA, Tura BR, Coelho HS, Ribeiro J, Fernandes ES, Schmal AF, Victor L, Luiz RR, Perez RM. Risk factors for long-term mortality in a large cohort of patients wait-listed for liver transplantation in Brazil. Liver Transpl. 2011;17(9):1013–20. · DOI
  3. Kazuhiko K, Kimianori N, Takashi T. BDNF gene-modified mesenchymal stem cells promote functional recovery and reduced infarct size in the rat middle cerebral artery occlusion model. Mol Ther. 2004;9(2):189–97. · DOI
  4. Gao J, Dennis JE, Muzic RF, Lundberq M, Caplan A. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. 2001;169(1):12–20. · DOI
  5. Gherardi E, Birchmeier W, Birchmeier C, Vande WG. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103. · DOI
  6. Zhu C, Li Y, Li W, Wu Q, Gao R. Gene transfer of c-met confers protection against D-galactosamine/lipopolysaccharide-induced acute liver failure. Dig Dis Sci. 2012;57(4):925–34. · DOI
  7. Zheng S, Yang J, Tang Y, Yang J, Shao Q, Guo L, Liu Q. Effect of bone marrow mesenchymal stem cells transplantation on the serum and liver HMGB1 expression in rats with acute liver failure. Int J Clin Exp Pathol. 2015;8(12):15985–92.
  8. Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol. 2007;20(1):S3–14. · DOI
  9. Li D, Fan J, He X, Zhang X, Zhang Z, Zeng Z, Ruan M, Cai L. Therapeutic effect comparison of hepatocyte-like cells and bone marrow mesenchymal stem cells in acute liver failure of rats. Int J Clin Exp Pathol. 2015;8(1):11–24.
  10. Tsolalo E, Yannaki E. Stem cell-based regenerative opportunities for the liver: state of the art and beyond. World J Gastroenterol. 2015;21(43):12334–50. · DOI
  11. Lorenzini S, Gitto S, Grandini E, Andreone P, Bernardi M. Stem cells for end stage liver disease: how far have we got? World J Gastroenterol. 2008;14(29):4593–99. · DOI
  12. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726–36. · DOI
  13. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells. 2007;25(11):2896–902. · DOI
  14. Yuan SF, Jiang T, Sun LH, Zheng RJ, Cao GQ, Ahat NZ, Zhang YX. Use of bone mesenchymal stem cells to treat rats with acute liver failure. Genet Mol Res. 2014;13(3):6962–80. · DOI
  15. Houlihan DD, Newsome PN. Critical review of clinical trials of bone marrow stem cells in liver disease. Gastroenterology. 2008;135(2):438–50. · DOI
  16. Thorqeirsson SS, Grisham JW. Hematopoietic cells as hepatocyte stem cells: a critical review of the evidence. Hepatology. 2006;43(1):2–8. · DOI
  17. Salomone F, Barbagallo I, Puzzo L, Piazza C, Li VG. Efficacy of adipose tissue-mesenchymal stem cell transplantation in rats with acetaminophen liver injury. Stem Cell Res. 2013;11(3):1037–44. · DOI
  18. van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, Yarmush ML. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology. 2008;47(5):1634–43. · DOI · Paper page
  19. Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, Zheng YB, Gao ZL. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011;54(3):820–8. · DOI
  20. Böhm F, Köhler UA, Speicher T, Werner S. Regulation of liver regeneration by growth factors and cytokines. EMBO Mol Med. 2010;2(8):294–305. · DOI
  21. Nejak-Bowen K, Orr A, Bowen Jr WC, Michalopoulos GK. Conditional genetic elimination of hepatocyte growth factor in mice compromises liver regeneration after partial hepatectomy. PLoS One. 2013;8(3):e59836. · DOI
  22. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A. 2001;98(1):247–52. · DOI
  23. Valdés-Arzate A, Luna A, Bucio L, Licona C, Clemens DL, Souza V, Hernandez E, Kershenobich D, Gutiérrez-Ruiz MC, Gómez-Quiroz LE. Hepatocyte growth factor protects hepatocytes against oxidative injury induced by ethanol metabolism. Free Radic Biol Med. 2009;47(4):424–30. · DOI
  24. Huh CG, Factor VM, Sánchez A, Uchida K, Conner EA, Thorqeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A. 2004;101(13):4477–82. · DOI · Paper page
  25. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 1995;373(6516):699–702. · DOI
  26. Shibata S, Miwa T, Wu HH, Levitt P, Ohyama T. Hepatocyte growth factor-c-met signaling mediates the development of nonsensory structures of the mammalian cochlea and hearing. J Neurosci. 2016;36(31):8200–9. · DOI
  27. Leung E, Xue A, Wang Y, Rougerie P, Sharma VP, Eddy R, Cox D, Condeelis J. Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway. Oncogene. 2017;36(19):2680-92. · DOI
  28. Zhu CL, Li YW, Gao RT. Gene therapy for acute liver failure. Curr Gene Ther. 2010;10(2):156–66. · DOI
  29. Booth C, Gaspar HB, Thrasher AJ. Treating Immunodeficiency through HSC gene therapy. Trends Mol Med. 2016;22(4):317–27. · DOI
  30. Kelly MJ, O’Keeffe GW, Sullivan AM. Viral vector delivery of neurotrophic factors for Parkinson's disease therapy. Expert Rev Mol Med. 2015;17:e8. · DOI
  31. McCarron A, Donnelley M, Mclntyre C, Parsons D. Challenges of up-scaling lentivirus production and processing. J Biotechnol. 2016;240:23–30. · DOI
  32. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Zhang M, Ihriq MM, McManus MT, Gertler FB, Scott ML, Van Parijs L. A lentivirus based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2013;33(3):401–6. · DOI
  33. Xiao Ling K, Peng L, Jian Feng Z, Wei C, Wei Yan Y, Nan S, Cheng Qi G, Zhi Wei W. Stromal derived factor-1/CXCR4 axis involved in bone marrow mesenchymal stem cells recruitment to injured liver. Stem Cells Int. 2016;2016:8906945. · DOI
  34. Liu N, Patzak A, Zhang J. CXCR4-overexpressing bone marrow-derived mesenchymal stem cells improve repair of acute kidney injury. Am J Physiol Renal Physiol. 2013;305(7):F1064–73. · DOI
  35. Ma HC, Shi XL, Ren HZ, Yuan XW, Ding YT. Targeted migration of mesenchymal stem cells modified with CXCR4 to acute failing liver improves liver regeneration. World J Gastroenterol. 2014;20(40):14884–94. · DOI · Paper page
  36. Benabdellah K, Muñoz P, Cobo M, Gutierrez-Guerrero A, Sánchez-Hernández S, Garcia-Perez A, Anderson P, Carrillo-Gálvez AB, Toscano MG, Martin F. Lent-On-Plus lentiviral vectors for conditional expression in human stem cells. Sci Rep. 2016;6:37289. · DOI

Cited by

Sorted by citations

Metadata

Authors
Wang, K., Li, Y., Zhu, T., Zhang, Y., Li, W., Lin, W., Li, J., & Zhu, C.
Affiliations
  • Anhui Medical University (CN)
  • Jiangsu Province Hospital (CN)
  • Harvard University (US)
Corresponding author
Zhu, Chuanlong
ORCID
Venue
Stem Cell Research & Therapy
Publisher
Springer Science and Business Media LLC
Published
2017-07-05
Volume
8
Issue
1
Pages
162-162
ISSN
1757-6512 (ISSN-L)
DOI
10.1186/s13287-017-0614-2
PMC
PMC5499016
OpenAlex
W2730810791
Cited by
54
References
1
Citations by year
2026: 4 · 2025: 4 · 2024: 13 · 2023: 7 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 5
FWCI
2.36
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81271713)
  • the Gilead Sciences Research Scholars Program in Liver Disease – Asia
  • the Key Medical Talents Fund of Jiangsu Province.
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
c-Met, bone marrow mesenchymal stem cells, acute liver failure, stem cell homing, hepatocyte growth factor, cell migration, liver regeneration, stem cell transplantation, gene overexpression
MeSH terms
Animals, Bone Marrow Cells, Disease Models, Animal, Liver, Male, Transduction, Genetic, Lentivirus, Liver Failure, Acute, Rats, Sprague-Dawley, Proto-Oncogene Proteins c-met, Mesenchymal Stem Cell Transplantation, Rats, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review